Introduction {#s1}
============

Gastric cancer remains the fifth most frequent malignancy and the third leading cause of cancer deaths globally ([@B1]). In China, 679,100 individuals were diagnosed with gastric cancer, and 498,000 gastric cancer-related deaths occurred in 2015 ([@B2]). Despite the development of multimodal treatments including surgery, traditional chemotherapy, and the implementation of neoadjuvant therapy, which can greatly improve the prognosis, gastric cancer is still a deadly disease with a poor clinical outcome ([@B3]). However, an accurate method to predict the prognosis of gastric cancer patients simply and effectively is not yet available.

The spleen is the largest peripheral immune organ and participates in the regulation of immune homoeostasis, but its role has been ignored among clinicians ([@B4], [@B5]). Diffuse reduction of spleen density (DROSD) is an imaging manifestation in the abdominal computed tomography (CT), which was originally reported in patients with acute pancreatitis (AP) ([@B6]). Meanwhile, in our long-term clinical practice, we also observed that this phenomenon existed in some gastric cancer patients. Interestingly, the post-operative prognosis of these patients was more serious. Some scholars found that AP patients with DROSD had more severe immune dysfunction than without ([@B7]). The host immune system is relevant to cancer development and progression ([@B8], [@B9]). Currently, there is a paucity of studies investigating the impact of DROSD in gastric cancer patients.

This study aimed to investigate whether DROSD, as determined by decreased CT values of the spleen, would predict post-operative outcomes in a cohort of patients after curative gastrectomy for gastric cancer.

Methods {#s2}
=======

Study Patients
--------------

This retrospective study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University. From June 2014 to December 2015, only patients who underwent curative gastrectomy for gastric cancer were included, with the following criteria: (1) patients who underwent preoperative abdominal CT scans and had a serological examination within 1 month before surgery and (2) those who are willing to participate in this study and provide informed consent. The following patients were excluded: (1) patients with past histories of splenic diseases, (2) those who have hematological system disease such as lymphoma, (3) those who have severe preoperative infection, (4) those who have incomplete medical records, (5) those who underwent a palliative surgery, and (6) those who undergone neoadjuvant chemotherapy. We collected and analyzed the data from the remaining 395 GC patients who underwent radical gastrectomy in the First Affiliated Hospital of Wenzhou Medical University and the Second Affiliated Hospital of Wenzhou Medical University. The experimental flow chart is shown in [Figure 1](#F1){ref-type="fig"}. All patients underwent conventional therapy following the Japanese Gastric Cancer Treatment Guidelines ([@B10]).

![Block flow chart of experimental grouping.](fonc-10-01050-g0001){#F1}

Data Collection
---------------

We prospectively collected and analyzed the following data in this study: (1) age; gender; body mass index (BMI); Nutritional Risk Screening 2002 (NRS 2002) scores; albumin and hemoglobin concentration; platelet/lymphocyte ratio (PLR); neutrophil/lymphocyte ratio (NLR); sarcopenia; Charlson Comorbidity Index; the American Society of Anaesthesiologists (ASA) grade; hypertension; diabetes mellitus; previous abdominal surgery; differentiation of tumors; tumor location, size and TNM stage (preoperative patients and disease characteristics aspect); (2) laparoscopy-assisted, type of resection, combined resection, and type of reconstruction (the operative details aspect); and (3) long-term overall survival (any causes of deaths), postoperative complications and readmission within 1 month after surgery (the postoperative outcomes aspect).

Measurement of the Spleen Density
---------------------------------

Spleen densities of patients with gastric cancer were measured at the Department of Radiology of the First Affiliated Hospital of Wenzhou Medical University using the same scanning parameters. In short, location conditions included 120 kV of the tube voltage, 50 mA of the tube current, 750 ms of tube circumrotation time, 5 mm of the layer thickness, and 5 mm of the layer spacing. Retrospective analysis of non-enhanced CT scan sequence images was performed by two investigators. As shown in [Figure 2](#F2){ref-type="fig"}, considering that the spleen density is affected by its own hemoperfusion, spleen CT values (Hounsfield units, HU) were measured at the upper pole, hilum, and inferior pole levels using a dedicated processing system (version 3.0.11.3 BN17 32 bit; INFINITT Healthcare Co. Ltd.). Spleen density was defined as the average of the three measurements of spleen CT values. In order to control for systematic errors, re-averaging of the spleen density measurements by the two investigators was ultimately performed. The mean of spleen density in this cohort were 46.95 HU (interquartile range, 43.91--49.80 HU).

![Abdominal CT scan of a gastric cancer patient with spleen density. The CT value of spleen at the **(A)** upper pole level, **(B)** the hilum level, and the **(C)** inferior pole level was 39.86, 50.20, and 50.13 HU, respectively.](fonc-10-01050-g0002){#F2}

The restrictive cubic splines by R Language was plotted to check whether spleen density is a linear risk structure. As shown in [Supplementary Figure 1](#SM1){ref-type="supplementary-material"}, the risk curve fluctuation obviously as spleen density gradually increases, considering the linear relationship is not very strong (*P* = 0.169). Therefore, categorical variable instead of continuous variable was used to analyze spleen density. To determine the spleen density cutoff values, with a mostly significant difference, we used optimum stratification to find the most significant *P*-value by means of log-rank chi-squared statistics ([@B11]). In the previous literature, this method has been presented to solve the threshold value of the continuous variable at which patients are best separated with respect to time to mortality ([@B12]). The cut-off values obtained by this method were used to classify patients into DROSD and non-DROSD.

Follow-Up
---------

All patients were required to come back and undergo the necessary examinations within the first month after surgery. After that, they were followed up every 3 months for further examinations as needed. Patients were contacted by phone and were scheduled to come back to the hospital to fulfill the follow-up program in the above time points. The follow-up program was consisted of a physical examination, laboratory tests, and ultrasonography and/or CT and/or endoscopy. Data on patient mortality, including time and cause of death, were obtained primarily through medical records, telephone follow-up and the local population database. Overall survival rate was determined as the proportion of all patients who survive after surgery for gastric cancer. Postoperative complication was recorded within a month after surgery, which was classified using the Clavien--Dindo (CD) Classification ([@B13]). Severe postoperative complications (SPCs) were defined as complications classified as Grade III or above. The date of the last follow-up was October 2018.

In this cohort, most of the patients were followed up by review of medical records and phone, and a small number of patients were contacted directly by phone. We eventually completed the follow-up work by retrieving data from the local population database for 29 patients who cannot be contacted by phone.

Statistical Analysis
--------------------

The Kolmogorov--Smirnov test was used to determine whether continuous data conform to normal distribution. Normal distribution, non-normal distribution, and categorical variables were presented as mean and standard deviation, median and interquartile range, and quantity and percentage, respectively. The Student\'s *t*-test was used to compare the data that conform to normal distribution. Mann--Whitney U-test was used to compare non-normally distributed data and Pearson chi-squared test or Fisher\'s exact test to compare categorical data. The outcome of this study was overall survival, calculated from the date of surgery to the date of death or last available follow-up. The Kaplan--Meier method was used to analyze the overall survival, and log-rank test was performed to compare the difference in survival between the subgroups. Multivariate Cox proportional hazards regression analysis was performed to determine the independent risk factors for long-term overall survival. Variables with *P* \< 0.10 in a univariate analysis were included in the multivariate analysis, and variables with *P* \< 0.05 were retained ultimately in the multivariate model.

All tests were two-tailed and were considered to be statistically significant when *P* \< *0.05*. All data were analyzed using the SPSS Statistics version 20.0 (IBM, Armonk, New York, USA).

Results {#s3}
=======

Baseline Characteristics
------------------------

From June 2014 to December 2015, a total of 395 patients met our criteria and were included for analysis. Demographic and clinical characteristics of patients with gastric cancer are represented in [Table 1](#T1){ref-type="table"}.

###### 

Patient demographic and clinical characteristics.

  **Factors**                                                     **Total (*n =* 395)**   **DROSD (*n =* 98)**   **non-DROSD (*n =* 297)**   ***P*-values**
  --------------------------------------------------------------- ----------------------- ---------------------- --------------------------- ---------------------------------------
  Age, median, years[**\***](#TN1){ref-type="table-fn"}           65 (58--73)             66 (60--73)            64 (57--73)                 0.735
  Gender                                                                                                                                     0.799
   Male                                                           302 (76.5)              74 (75.5)              228 (76.8)                  
   Female                                                         93 (23.5)               24 (45.5)              69 (23.2)                   
  BMI (kg/cm2)[\*](#TN1){ref-type="table-fn"}                     22.17 (20.21--24.22)    22.83 (20.47--24.61)   22.07 (20.20--24.03)        0.095
  NRS score                                                                                                                                  0.763
   1--2                                                           242 (61.3)              62 (63.3)              180 (60.6)                  
   3--4                                                           122 (30.9)              28 (28.6)              94 (31.6)                   
   5--6                                                           31 (7.8)                8 (8.1)                23 (7.7)                    
   Preoperative albumin (g/L)[\*](#TN1){ref-type="table-fn"}      37.9 (34.6--40.9)       36.9 (33.8--39.8)      38.6 (35.0--41.3)           0.405
   Preoperative hemoglobin (g/L)[\*](#TN1){ref-type="table-fn"}   123.5 (105.0--136.0)    112.0 (90.0--131.5)    126.0 (111.0--137.0)        \<0.001[‡](#TN2){ref-type="table-fn"}
   PLR[\*](#TN1){ref-type="table-fn"}                             149.7 (114.2--205.8)    163.5 (121.9--228.6)   142.4 (109.4--200.8)        0.196
   NLR[\*](#TN1){ref-type="table-fn"}                             2.27 (1.74--3.24)       2.62 (2.02--3.56)      2.18 (1.66--3.11)           0.013[‡](#TN2){ref-type="table-fn"}
  Sarcopenia                                                                                                                                 0.094
   No                                                             310 (78.5)              71 (72.4)              239 (80.5)                  
   Yes                                                            85 (21.5)               27 (27.6)              58 (19.5)                   
  Charlson comorbidity index                                                                                                                 0.058
   0                                                              203 (51.4)              42 (42.9)              161 (54.2)                  
   1--2                                                           179 (45.3)              52 (53.1)              127 (42.8)                  
   3--6                                                           13 (3.3)                4 (4.0)                9 (3.0)                     
  ASA score                                                                                                                                  0.098
   1--2                                                           317 (80.3)              73 (76.0)              244 (82.2)                  
   3--4                                                           78 (19.7)               25 (24.0)              53 (17.8)                   
  Hypertension                                                                                                                               0.017[‡](#TN2){ref-type="table-fn"}
   No                                                             294 (74.4)              64 (65.3)              230 (77.4)                  
   Yes                                                            101 (25.6)              34 (34.7)              67 (22.6)                   
  Diabetes Mellitus                                                                                                                          0.208
   No                                                             345 (87.3)              82 (83.7)              263 (88.6)                  
   Yes                                                            50 (12.7)               16 (16.3)              34 (11.4)                   
  Previous abdominal surgery                                                                                                                 0.179
   No                                                             343 (86.8)              89 (90.8)              254 (85.5)                  
   Yes                                                            52 (13.2)               9 (9.2)                43 (14.5)                   
  Differentiated Types                                                                                                                       0.993
   Undifferentiated                                               29 (7.3)                6 (6.1)                23 (7.7)                    
   Differentiated                                                 300 (75.9)              75 (76.5)              225 (75.8)                  
   Signet-ring cell                                               66 (16.8)               17 (17.4)              49 (16.5)                   
  Tumor site                                                                                                                                 0.401
   Cardia                                                         49 (12.4)               9 (9.2)                40 (13.4)                   
   Gastric body                                                   77 (19.5)               21 (21.4)              56 (18.7)                   
   Antrum                                                         253 (64.0)              63 (64.3)              190 (64.2)                  
   Diffuse                                                        16 (4.1)                5 (5.1)                11 (3.7)                    
   Tumor size (cm)[\*](#TN1){ref-type="table-fn"}                 4.00 (2.00--5.50)       5.00 (2.75--6.00)      3.50 (2.00--5.00)           0.005[‡](#TN2){ref-type="table-fn"}
  TNM stages                                                                                                                                 0.095
   I                                                              113 (28.6)              22 (22.4)              91 (30.6)                   
   II                                                             78 (19.7)               19 (19.4)              59 (19.9)                   
   III                                                            204 (51.6)              57 (58.2)              147 (49.5)                  
  Total gastric resection                                                                                                                    0.467
   No                                                             242 (61.3)              57 (58.2)              185 (62.3)                  
   Yes                                                            153 (38.7)              41 (41.8)              112 (37.7)                  
  Combined resection                                                                                                                         0.467
   No                                                             358 (90.6)              87 (88.8)              271 (91.2)                  
   Yes                                                            37 (9.4)                11 (11.2)              26 (8.8)                    
  Laparoscopy-assisted surgery                                                                                                               0.438
   No                                                             317 (80.3)              76 (77.6)              241 (81.8)                  
   Yes                                                            78 (19.7)               22 (22.4)              56 (18.9)                   
  Type of reconstruction                                                                                                                     0.620
   Roux-en-Y                                                      173 (43.8)              45 (45.9)              128 (43.1)                  
   Billroth I                                                     149 (37.7)              36 (36.7)              113 (38.0)                  
   Billroth II                                                    73 (18.5)               17 (17.4)              56 (18.9)                   
  C-D classification                                                                                                                         0.030[‡](#TN2){ref-type="table-fn"}
    ≤ 1                                                           302 (76.5)              67 (68.4)              235 (79.1)                  
   ≥2                                                             93 (23.5)               31 (31.6)              62 (20.9)                   
  Readmission of 30 days                                                                                                                     0.765
   No                                                             364 (92.2)              91 (92.9)              273 (91.9)                  
   Yes                                                            31 (7.8)                7 (7.1)                24 (8.1)                    

*BMI, body mass index; NRS, nutritional risk screening; PLR, platelet/lymphocyte ratio; NLR, neutrophil/lymphocyte ratio; ASA, American Society of Anaesthesiologists; diffuse, linitis plastic; TNM, tumor-node-metastasis; C-D complication classification, Clavien-Dindo complication classification*.

*Values are number of patients and percent unless indicated otherwise*;

*Values are median (inter quartile range)*;

*Values are statistically significant (P \< 0.05)*.

Cutoff Values for Diffuse Reduction of Spleen Density (DROSD)
-------------------------------------------------------------

Cutoff value for DROSD associated with long-term overall survival was 43.89 HU. Using this cutoff value, 98 (24.8%) patients were found to have DROSD. As shown in [Table 1](#T1){ref-type="table"}, patients with DROSD had a lower preoperative hemoglobin level, higher NLR, hypertension, larger tumor size and poorer C--D Classification than those without DROSD (all *P* \< 0.05).

Actual Number and Frequency of Each Complication
------------------------------------------------

As [Table 2](#T2){ref-type="table"} shows, there were 157 postoperative events involving 93 patients (23.5%). Of them, 42 (10.6%) patients had grade IIIa or higher PCs. Pulmonary complications, which mainly included pulmonary infections and pleural effusions, and intra-abdominal infections were the most frequent PCs. Postoperative infection complications were included Grade II or above wound infection, pulmonary infections and intra-abdominal infections.

###### 

Actual number and frequency of each complication (Grade ≥ II).

  **Complication**                        **Total (*n =* 395)**   **DROSD (*n =* 98)**   **non-DROSD (*n =* 297)**   ***P*-values**
  --------------------------------------- ----------------------- ---------------------- --------------------------- --------------------------------------
  Wound infection                         3 (0.8)                 1 (1.0)                2 (0.7)                     \>0.05
  Intra-abdominal infection               34 (6.1)                10 (10.2)              24 (8.1)                    \>0.05
  Pulmonary                               32 (8.1)                16 (16.3)              16 (5.4)                    \<0.01[‡](#TN4){ref-type="table-fn"}
  Anastomotic leakage                     12 (3.0)                3 (3.1)                9 (3.0)                     \>0.05
  Thrombosis                              13 (3.3)                6 (6.1)                7 (2.4)                     \>0.05
  Bowel obstruction                       11 (2.8)                2 (2.0)                9 (3.0)                     \>0.05
  Postoperative bleeding                  13 (3.3)                5 (5.1)                8 (2.7)                     \>0.05
  Gastroparesis                           4 (1.0)                 1 (1.0)                3 (1.0)                     \>0.05
  Hepatic                                 4 (1.0)                 3 (3.1)                1 (0.3)                     \<0.05[‡](#TN4){ref-type="table-fn"}
  Lymphorrhagia                           4 (1.0)                 0 (0.0)                3 (1.0)                     \>0.05
  Renal                                   2 (0.5)                 1 (1.0)                1 (0.3)                     \>0.05
  Heart                                   2 (0.5)                 0 (0.0)                2 (0.7)                     \>0.05
  Hypoalbuminemia                         10 (2.5)                2 (2.0)                8 (2.7)                     \>0.05
  Others[\*](#TN3){ref-type="table-fn"}   8 (2.0)                 3 (3.1)                5 (1.7)                     \>0.05
  Death                                   5 (1.3)                 3 (3.1)                2 (0.7)                     \>0.05

*Values are number of each complication and percent unless indicated otherwise*;

*Others contain one severe complication (Abdominal pseudocyst formation) and seven mild complications (depression, skin allergies, oral herpes, thrush, delirium, hiccups and acute gout attack.)*;

*Values are statistically significant (P \< 0.05); The chi-square test is used for P-values*.

Univariate and Multivariate Logistic Regression Analyses for Postoperative Complications (PCs)
----------------------------------------------------------------------------------------------

On univariate analysis, age (*P* = 0.004), NRS score (*P* = 0.057), Charlson comorbidity index (*P* = 0.037), diabetes mellitus (*P* = 0.071), combined resection (*P* = 0.002), laparoscopy-assisted (*P* = 0.010), and DROSD (*P* = 0.013) differed significantly ([Table 3](#T3){ref-type="table"}). Significant variables on univariate analysis were included in the multivariate logistic regression analysis. Age (OR = 2.459, *P* = 0.014), Combined resection (OR = 3.495, *P* = 0.004), laparoscopy-assisted (OR = 0.222, *P* = 0.044), and DROSD (OR = 2.390, *P* = 0.014) were independently associated with SPCs.

###### 

Univariate and multivariate analysis associated with severe post-operative complications.

  **Factors**                    **Univariate analysis**   **Multivariate analysis**                                                                
  ------------------------------ ------------------------- --------------------------- ------------------------------------- ---------------------- -------------------------------------
  Age, years                                                                           0.004[‡](#TN5){ref-type="table-fn"}   2.459 (1.200--5.040)   0.014[‡](#TN5){ref-type="table-fn"}
    \< 75                        292 (82.7)                27 (67.5)                                                                                
   ≥75                           61 (17.3)                 15 (32.5)                                                                                
  Gender                                                                               0.669                                                        
   Female                        82 (23.2)                 11 (26.2)                                                                                
   Male                          271 (76.8)                31 (73.8)                                                                                
   BMI, kg/cm2                                                                         0.703                                                        
   \<25                          294 (83.3)                34 (81.0)                                                                                
   ≥25                           59 (16.7)                 8 (19.0)                                                                                 
  NRS score                                                                            0.057                                                        
   1--2                          218 (61.8)                24 (57.1)                                                                                
   3--4                          113 (32.0)                9 (21.4)                                                                                 
   5--6                          22 (6.2)                  9 (21.5)                                                                                 
  Hypoalbuminemia, g/L                                                                 0.306                                                        
   No (\<30)                     343 (97.2)                39 (92.9)                                                                                
   Yes (≥30)                     10 (2.8)                  3 (7.1)                                                                                  
  Anemia                                                                               0.848                                                        
   No                            290 (82.2)                34 (81.0)                                                                                
   Yes                           63 (17.8)                 8 (19.0)                                                                                 
  PLR                                                                                  0.609                                                        
    ≤ 92.8                       39 (11.0)                 3 (7.1)                                                                                  
   \>92.8                        314 (89.0)                39 (92.9)                                                                                
  NLR                                                                                  0.112                                                        
    ≤ 2.75                       229 (64.9)                22 (52.4)                                                                                
   \>2.75                        124 (35.1)                20 (47.6)                                                                                
  CCI                                                                                  0.037[‡](#TN5){ref-type="table-fn"}                          
   0                             188 (53.3)                15 (35.7)                                                                                
   1--2                          154 (43.6)                25 (59.5)                                                                                
   3--6                          11 (3.1)                  2 (4.8)                                                                                  
  ASA score                                                                            0.129                                                        
   1--2                          287 (81.3)                30 (71.4)                                                                                
   3--4                          66 (18.7)                 12 (28.6)                                                                                
  Hypertension                                                                         0.398                                                        
   No                            265 (75.1)                29 (69.0)                                                                                
   Yes                           88 (24.9)                 13 (31.0)                                                                                
  Diabetes Mellitus                                                                    0.071[‡](#TN5){ref-type="table-fn"}                          
   No                            312 (88.4)                33 (78.6)                                                                                
   Yes                           41 (11.6)                 9 (21.4)                                                                                 
  Tumor size, cm                                                                       0.380                                                        
    \<4.75                       218 (61.8)                23 (54.8)                                                                                
   ≥4.75                         135 (38.2)                19 (45.2)                                                                                
  TNM stages                                                                           0.159                                                        
   I, II                         175 (49.6)                16 (38.1)                                                                                
   III                           178 (50.4)                26 (61.9)                                                                                
  Total gastrectomy                                                                    0.360                                                        
   No                            219 (62.0)                23 (54.8)                                                                                
   Yes                           134 (38.0)                19 (45.2)                                                                                
  Combined resection                                                                   0.002[‡](#TN5){ref-type="table-fn"}   3.495 (1.504--8.123)   0.004[‡](#TN5){ref-type="table-fn"}
   No                            326 (92.4)                32 (76.2)                                                                                
   Yes                           27 (7.6)                  10 (23.8)                                                                                
  Laparoscopy-assisted surgery                                                         0.010[‡](#TN5){ref-type="table-fn"}   0.222 (0.051--0.960)   0.044[‡](#TN5){ref-type="table-fn"}
   No                            277 (78.5)                40 (95.2)                                                                                
   Yes                           76 (21.5)                 2 (4.8)                                                                                  
  DROSD                                                                                0.013[‡](#TN5){ref-type="table-fn"}   2.390 (1.197--4.772)   0.014[‡](#TN5){ref-type="table-fn"}
   No                            272 (77.1)                25 (59.5)                                                                                
   Yes                           81 (22.9)                 17 (40.5)                                                                                

*SPC, severe postoperative complications; BMI, body mass index; PLR, platelet/lymphocyte ratio; NLR, neutrophil/lymphocyte ratio; ASA, American Society of Anesthesiologists; Charlson comorbidity index, CCI; NRS, nutritional risk screening; TNM, tumor-node-metastasis*.

*Values are number of patients and percent unless indicated otherwise*;

*Values are statistically significant (P \< 0.05)*.

Based on above results, we also evaluate the relationship between DORSD and postoperative infection complications. On univariate analysis, hypoalbuminemia (*P* = 0.082), NLR (*P* = 0.002), charlson comorbidity index (*P* \< 0.001), ASA grade (*P* = *0.031*), tumor size (*P* = 0.003), TNM stages (*P* = 0.004), total gastrectomy (*P* = 0.006), combined resection (*P* = 0.063), laparoscopy-assisted (*P* = 0.004) and DROSD (*P* = 0.018) differed significantly ([Table 4](#T4){ref-type="table"}). On multivariate analysis, NLR (OR = 1.880, *P* = 0.040), charlson comorbidity index (OR = 2.457, *P* = 0.001), tumor size (OR = 2.105, *P* = 0.016) and laparoscopy-assisted (OR = 0.264, *P* = 0.031) were independently associated with postoperative infectious complications (all *P* \< *0.05*).

###### 

Univariate1 and multivariate analysis associated with post-operative infection complications.

  **Factors**                    **Univariate analysis**   **Multivariate analysis**                                                                  
  ------------------------------ ------------------------- --------------------------- --------------------------------------- ---------------------- -------------------------------------
  Age, years                                                                           0.654                                                          
   \<75                          275 (81.1)                44 (78.6)                                                                                  
   ≥75                           64 (18.9)                 12 (21.4)                                                                                  
  Gender                                                                                                                                              
   Female                        82 (24.2)                 11 (19.6)                   0.458                                                          
   Male                          257 (75.8)                45 (80.4)                                                                                  
  BMI, kg/cm^2^                                                                        0.336                                                          
   \<25                          284 (83.8)                44 (78.6)                                                                                  
   ≥25                           55 (16.2)                 12 (21.4)                                                                                  
  NRS score                                                                            0.665                                                          
   1--2                          209 (61.7)                33 (58.9)                                                                                  
   3--4                          104 (30.7)                18 (32.1)                                                                                  
   5--6                          26 (7.6)                  5 (9.0)                                                                                    
  Hypoalbuminemia, g/L                                                                 0.082                                                          
   No (\<30)                     330 (97.3)                52 (92.9)                                                                                  
   Yes (≥30)                     9 (2.7)                   4 (7.1)                                                                                    
  Anemia                                                                               0.467                                                          
   No                            280 (82.6)                44 (78.6)                                                                                  
   Yes                           59 (17.4)                 12 (21.4)                                                                                  
  PLR                                                                                  0.655                                                          
    ≤ 92.8                       37 (10.9)                 5 (8.9)                                                                                    
   \>92.8                        302 (89.1)                51 (91.1)                                                                                  
  NLR                                                                                  0.002[‡](#TN6){ref-type="table-fn"}     1.880 (1.028--3.439)   0.040[‡](#TN6){ref-type="table-fn"}
    ≤ 2.75                       226 (66.7)                25 (44.6)                                                                                  
   \>2.75                        113 (33.3)                31 (55.4)                                                                                  
  CCI                                                                                  \<0.001[‡](#TN6){ref-type="table-fn"}   2.457 (1.452--4.519)   0.001[‡](#TN6){ref-type="table-fn"}
   0                             188 (55.5)                15 (26.8)                                                                                  
   1--2                          142 (41.9)                37 (66.1)                                                                                  
   3--6                          9 (2.6)                   4 (7.1)                                                                                    
  ASA score                                                                            0.031[‡](#TN6){ref-type="table-fn"}                            
   1--2                          278 (82.0)                39 (69.6)                                                                                  
   3--4                          61 (18.0)                 17 (30.4)                                                                                  
  Hypertension                                                                         0.122                                                          
   No                            257 (75.8)                37 (66.1)                                                                                  
   Yes                           82 (24.2)                 19 (33.9)                                                                                  
  Diabetes Mellitus                                                                    0.207                                                          
   No                            299 (88.2)                46 (82.1)                                                                                  
   Yes                           40 (11.8)                 10 (17.9)                                                                                  
  Tumor size, cm                                                                       0.003[‡](#TN6){ref-type="table-fn"}     2.105 (1.147--3.860)   0.016[‡](#TN6){ref-type="table-fn"}
    \<4.75                       217 (64.0)                24 (42.9)                                                                                  
   ≥4.75                         122 (36.0)                32 (57.1)                                                                                  
  TNM stages                                                                           0.004[‡](#TN6){ref-type="table-fn"}                            
   I, II                         174 (51.3)                17 (30.3)                                                                                  
   III                           165 (48.7)                39 (69.7)                                                                                  
  Total gastrectomy                                                                    0.006[‡](#TN6){ref-type="table-fn"}                            
   No                            217 (64.0)                25 (44.6)                                                                                  
   Yes                           122 (36.0)                31 (55.4)                                                                                  
  Combined resection                                                                   0.063                                                          
   No                            311 (91.7)                47 (83.9)                                                                                  
   Yes                           28 (8.3)                  9 (16.1)                                                                                   
  Laparoscopy-assisted surgery                                                         0.004[‡](#TN6){ref-type="table-fn"}     0.264 (0.079--0.887)   0.031[‡](#TN6){ref-type="table-fn"}
   No                            264 (77.9)                53 (94.6)                                                                                  
   Yes                           75 (22.1)                 3 (5.4)                                                                                    
  DROSD                                                                                0.018[‡](#TN6){ref-type="table-fn"}     1.693 (0.891--3.219)   0.108
   No                            262 (77.3)                35 (62.5)                                                                                  
   Yes                           77 (22.7)                 21 (37.5)                                                                                  

*PIC, postoperative infection complications; BMI, body mass index; PLR, platelet/lymphocyte ratio; NLR, neutrophil/lymphocyte ratio; ASA, American Society of Anesthesiologists; Charlson comorbidity index, CCI; NRS, nutritional risk screening; TNM, tumor-node-metastasis*.

*Values are number of patients and percent unless indicated otherwise*;

*Values are statistically significant (P \< 0.05)*.

DROSD and Overall Survival (OS) Rate
------------------------------------

We excluded 4 patients who died within 1 month after surgery in order to better study the relationship between DROSD and OS. The remaining 391 patients were included in the analysis. The median follow-up duration was 39.2 months (range, 18.3--45.5 months). At the last follow-up, 151 (38.6%) patients died.

As shown in [Figure 3](#F3){ref-type="fig"}, patients with DROSD had a poorer OS rate than those without DROSD (*P* \< 0.001). The 1- and 3-year overall survival rates were 76.0 and 45.8%, respectively, for patients with DROSD, and were 87.8 and 66.4%, respectively, for those without DROSD. The median OS was shorter in patients with DROSD than in those without DROSD (28.9 vs. 51.7 months; *P* \< 0.001; [Figure 3](#F3){ref-type="fig"}).

![Kaplan--Meier survival curves for overall survival in patients with and in those without DROSD. Two curves were compared using log-rank test.](fonc-10-01050-g0003){#F3}

We further assessed the prognostic value of DROSD in different TNM stage groups. The results revealed that preoperative spleen density was a prognostic indicator in patients with stage II (*P* = 0.014; [Figure 4A](#F4){ref-type="fig"}) and stage III (*P* = 0.017; [Figure 4C](#F4){ref-type="fig"}) gastric cancer. However, for patients with stage I gastric cancer, no significant association of spleen density with OS was identified (*P* = 0.560; [Figure 4B](#F4){ref-type="fig"}).

![Kaplan--Meier survival curves for overall survival in patients with and in those without DROSD under adjusted TNM stage. Overall survival of patients with **(A)** TNM stage I; **(B)** TNM stage II; and **(C)** TNM stage III gastric cancer.](fonc-10-01050-g0004){#F4}

Univariate and Multivariate Cox Regression Analysis for OS Rate
---------------------------------------------------------------

As shown in [Table 5](#T5){ref-type="table"}, in a univariate analysis, age (*P* \< 0.0001), NRS 2002 scores (*P* \< 0.0001), hypoalbuminemia (*P* = 0.001), NLR (*P* = 0.008), Charlson Comorbidity Index (*P* \< 0.0001), ASA grade (P = 0.057), hypertension (*P* = 0.012), differentiation of tumor (*P* \< 0.0001), tumor location (*P* \< 0.0001), tumor size (*P* \< 0.0001), TNM stage (*P* \< 0.0001), total gastrectomy (*P* \< 0.0001), combined resection (*P* \< 0.0001), laparoscopy-assisted surgery (*P* = *0.02*), type of reconstruction (*P* \< 0.0001), C--D Classification (*P* \< 0.0001), readmission within 30 days (*P* \< 0.016), and DROSD (*P* \< *0.0001*) were significant prognostic factors.

###### 

Univariate and multivariate analysis of factors associated with overall survival.

  **Factors**                         **Univariate analysis**   **Multivariate analysis**                                          
  ----------------------------------- ------------------------- ------------------------------------------ ----------------------- ------------------------------------------
  Age, years                                                                                                                       
   ≥75/ \<75                          1.987 (1.391--2.838)      \<0.0001[^‡^](#TN7){ref-type="table-fn"}   1.782 (1.218--2.608)    0.003[^‡^](#TN7){ref-type="table-fn"}
  Gender                                                                                                                           
   Male/female                        1.321 (0.886--1.971)      0.172                                                              
  BMI, kg/m2                                                                                                                       
   18.5--23.5/\<18.5                  0.730 (0.428--1.246)      0.249                                                              
   \>23.5/\<18.5                      0.676 (0.385--1.185)      0.171                                                              
  NRS 2002 scores                                                                                                                  
   3--4/1--2                          1.369 (0.962--1.948)      0.081                                                              
   5--6/1--2                          2.721 (1.666--4.444)      \<0.0001[^‡^](#TN7){ref-type="table-fn"}                           
  Hypoalbuminemia                                                                                                                  
   Yes/No                             3.061 (1.558--6.015)      0.001[^‡^](#TN7){ref-type="table-fn"}                              
  Anemia                                                                                                                           
   Yes/No                             1.176 (0.789--1.754)      0.426                                                              
  PLR                                                                                                                              
   \>92.8/≤92.8                       1.129 (0.662--1.924)      0.657                                                              
  NLR                                                                                                                              
   \>2.75/≤2.75                       1.545 (1.120--2.132)      0.008[^‡^](#TN7){ref-type="table-fn"}                              
  Charlson comorbidity index                                                                                                       
   1--2/0                             1.676 (1.201--2.340)      0.002[^‡^](#TN7){ref-type="table-fn"}      1.390 (0.980--1.974)    0.064
   3--6/0                             3.607 (1.845--7. 051)     \<0.0001[^‡^](#TN7){ref-type="table-fn"}   3.210 (1.600--6.400)    0.001[^‡^](#TN7){ref-type="table-fn"}
  ASA grade                                                                                                                        
   3--4/1--2                          1.433 (0.989--2.077)      0.057[^‡^](#TN7){ref-type="table-fn"}                              
  Hypertension                                                                                                                     
   Yes/No                             1.551 (1.101--2.185)      0.012[^‡^](#TN7){ref-type="table-fn"}                              
  Diabetes Mellitus                                                                                                                
   Yes/No                             1.034 (0.640--1.673)      0.890                                                              
  Previous abdominal surgery                                                                                                       
   Yes/No                             1.330 (0.860--2.058)      0.200                                                              
  Differentiation of tumor                                                                                                         
   Undifferentiated/Differentiated    2.463 (1.512--4.011)      \<0.0001[^‡^](#TN7){ref-type="table-fn"}                           
   Signet--ring cell/Differentiated   0.783 (0.491--1.248)      0.302                                                              
  Tumor location                                                                                                                   
   Gastric body/cardia                0.818 (0.465--1.441)      0.487                                      1.001 (0.558--1.797)    0.996
   Antrum/cardia                      0.757 (0.470--1.219)      0.251                                      1.593 (0.903--2.810)    0.108
   Diffuse/cardia                     4.791 (2.451--9.365)      \<0.0001[^‡^](#TN7){ref-type="table-fn"}   3.470 (1.690--7.127)    0.001[^‡^](#TN7){ref-type="table-fn"}
  Tumor size, cm                                                                                                                   
   ≥4.75/\<4.75                       2.681 (1.940--3.706)      \<0.0001[^‡^](#TN7){ref-type="table-fn"}                           
  TNM stage                                                                                                                        
   II/I                               2.978 (1.474--6.018)      0.002[^‡^](#TN7){ref-type="table-fn"}      2.780 (1.349--5.731)    0.006[^‡^](#TN7){ref-type="table-fn"}
   III/I                              7.555 (4.166--13.702)     \<0.0001[^‡^](#TN7){ref-type="table-fn"}   6.548 (3.561--12.039)   \<0.0001[^‡^](#TN7){ref-type="table-fn"}
  Total gastrectomy                                                                                                                
   Yes/No                             2.629 (1.904--3.631)      \<0.0001[^‡^](#TN7){ref-type="table-fn"}   2.433 (1.622--3.650)    \<0.0001[^‡^](#TN7){ref-type="table-fn"}
  Combined resection                                                                                                               
   Yes/no                             2.394 (1.534--3.735)      \<0.0001[^‡^](#TN7){ref-type="table-fn"}                           
  Laparoscopy-assisted surgery                                                                                                     
   Yes/no                             0.579 (0.365--0.918)      0.020[^‡^](#TN7){ref-type="table-fn"}                              
  Type of reconstruction                                                                                                           
   Billroth I/Roux-en-Y               0.277 (0.181--0.423)      \<0.0001[^‡^](#TN7){ref-type="table-fn"}                           
   Billroth II/Roux-en-Y              0.752 (0.502--1.125)      0.165                                                              
  C-D complication classification                                                                                                  
   ≥2/≤1                              2.230 (1.590--3.127)      \<0.0001[^‡^](#TN7){ref-type="table-fn"}                           
  Readmission of 30 days                                                                                                           
   Yes/No                             1.888 (1.125--3.171)      0.016[^‡^](#TN7){ref-type="table-fn"}      2.078 (1.206--3.583)    0.008[^‡^](#TN7){ref-type="table-fn"}
  Adjuvant chemotherapy                                                                                                            
   Yes/No                             1.111 (0.806--1.532)      0.519                                                              
   DROSD                                                                                                                           
   Yes/No                             1.897 (1.355--2.654)      \<0.0001[^‡^](#TN7){ref-type="table-fn"}   1.568 (1.106--2.223)    0.011[^‡^](#TN7){ref-type="table-fn"}

*BMI, body mass index; NRS, nutritional risk screening; PLR, platelet/lymphocyte ratio; NLR, neutrophil/lymphocyte ratio; ASA, American Society of Anaesthesiologists; diffuse, linitis plastic; TNM, tumor-node-metastasis, C-D complication classification, Clavien-Dindo complication classification; HR, hazards ratio; CI, confidence interval*.

*4 patients who died within 1 month after surgery was excluded in order to better study the relationship between DROSD and overall survival. The remaining 391 patients were included in the analysis*.

*values are statistically significant (P \< 0.05)*.

Significant variables in a univariate analysis were included in multivariate Cox regression analysis. We found that age (HR = 1.782, *P* = 0.003), Charlson Comorbidity Index of 3--6 (HR = 3.210, *P* = 0.001), diffuse gastric cancer (HR = 3.470, P = 0.001), advanced TNM stage (P \< 0.0001), total gastric resection (HR = 2.433, *P* \< 0.0001), readmission within 30 days (HR = 2.078, *P* = 0.008), and DROSD (HR = 1.568, *P* = 0.011) were independently associated with a lower OS rate.

Discussion {#s4}
==========

The topic of post-operative outcomes after curative gastrectomy is of great concern for both surgeons and patients ([@B14], [@B15]). To study the related factors affecting prognosis of gastric cancer and early identification of patients with a poor prognosis will be particularly meaningful ([@B16]). There are many indicators to predict the prognosis of gastric cancer ([@B17], [@B18]). The downside of TNM stage, a classic indicator of prognosis for gastric cancer, was determined postoperatively ([@B19]). Currently, lack of efficient means to early predict postoperative outcomes of patients has been considered as one of the obstacles for improve prognosis of gastric cancer.

In contrast, as an imaging evaluation method, the measurement of spleen density by CT is compatible with daily clinical practice because it is well-visualized, cost-effective, and can easily be diagnosed preoperatively. CT of the abdomen is currently the primary means of staging for gastric cancer and is widely available in clinical practice ([@B20]). However, the value of abdominal CT has not been fully reflected. Spleen density is a novel tool that can be used in clinical practices as a prognostic predictor for patients with gastric cancer. In the present study, we reported that the incidence rate of DROSD was up to 24.8% in the patient cohort. Furthermore, DROSD was identified as an independent risk factor for post-operative complications (OR = 2.390, *P* = 0.014) and long-term OS (HR = 1.568, *P* = 0.011) in gastric cancer. Through this paper, we hope that patients with poor prognosis can be screened early according to spleen density.

This is the first time we reported that DROSD has a negative impact on short- and long-term prognosis for patient after radical gastrectomy. The mechanisms by which DROSD confers increased risk of poor prognosis are still unclear, but the following reasons can be hypothesized. First, spleen is an abdominal parenchymal organ of the body ([@B21]). AP patients with DROSD have downregulated immune function, and DROSD patients had more severe lymphocytes decreased than non-DROSD patients ([@B7]). It is worth noting that immune function were associated with favorable prognosis for gastric cancer patients ([@B22]--[@B24]). Meantime, we also found that DROSD patients have a higher NLR level (*P* \< 0.05). NLR is an indicator of systemic inflammatory response ([@B25]). The higher NLR level can enhance the occurrence of inflammatory cytokine cascades ([@B26]) and negatively affect the immune system, which can partially explain the negative impact of DROSD on post-operative outcomes. Whether gastric cancer patients with DROSD have also experienced the function disorder of immunity, which lead to the patient having short- and long-term differences still requires further experimental verification. Second, it has been reported that splenic volume increase is a surrogate marker of inflammation cells accumulation and associated with worse long-term survival ([@B27], [@B28]). As mentioned in the previous literature, the reduction of spleen density in acute severe pancreatitis rats was related to the increase of spleen volume ([@B7]). There may be a correlation between the spleen density and the volume in human, which leads to spleen density associated with poor long-term prognosis. Third, some scholars have speculated that DROSD is caused by spleen fat infiltration ([@B6]). Does obesity affect the prognosis of cancer patients? Visceral fat area, as an evaluation index of obesity, can evaluate operative difficulties and is reportedly associated with post-operative complications ([@B29], [@B30]). However, BMI has little to do with long-term prognosis in the present study (*P* \> 0.05). Even the previous literature has pointed out that obesity is a protective factor for the long-term prognosis of cancer patients ([@B31]--[@B33]).

Spleen density is susceptible to many factors, such as hemoperfusion. The mechanism for the DROSD is not fully expounded. It has been reported that spleen density reduction is associated with lipid metabolism ([@B6]). Some animal experiments show that DROSD is not related to lipid deposition but hemoperfusion ([@B7]). The rich blood flow of spleen can change physical density, thereby affecting its density value on CT ([@B34], [@B35]). This is consistent with the result in [Table 1](#T1){ref-type="table"}, that is, DROSD is associated with hypertension and preoperative hemoglobin concentration (*P* \< 0.05). Whether DROSD is related to lipid metabolism or hemoperfusion needs to be further studied in animal and human studies. Meantime, we also noticed that NLR and others, as possible confounding factors of spleen density, can affecting the reliability of conclusion. Therefore, factors such as NLR and hypoalbuminemia were included in the multivariate analysis, and the results showed that DROSD was an independent risk factor that affected the post-operative outcome of gastric cancer patients.

We found that old age, charlson comorbidity index of 3--6, diffuse gastric cancer, advanced TNM stage, total gastric resection, and readmission within 30 days were associated with poor prognosis in patients with gastric cancer. The survival difference in the elderly patients and young patients can be partially explained by the dissimilarity in treatment ([@B36]). Liu et al. ([@B37]) found that the OS rate after distal gastrectomy for distal gastric cancer patients was higher than that after total gastrectomy. Moreover, some literature also pointed out that Charlson Comorbidity Index, diffuse gastric cancer, and readmission were also associated with poor long-term survival ([@B38]--[@B40]).

Similar to our research result, tumor staging is closely related to long-term prognosis of cancer ([@B17]). To objectively evaluate the impact of spleen density on the OS, we stratified the patients according to their TNM stage. The results showed that DROSD group has a significantly poorer OS than the non-DROSD group, under TNM stage II and III (*P* \< 0.05). However, for patients with TNM stage I, the difference was not significant, although there was a trend toward worse OS in the DROSD patients. Since patients with TNM stage I generally have a longer postoperative survival time, we propose that a longer follow-up period is needed to further research the effect of DROSD on long-term postoperative survival.

Our study had several potential limitations that should not be ignored. First, the data of this study were obtained only from double hospital, and a bias may exist due to the lack of multicenter validation of the research conclusions. Second, even we assigned two investigators to measure the spleen density together, the artificial measurement errors still exist.

Conclusions {#s5}
===========

DROSD is an independently risk factor for severe postoperative complications and long-term overall survival in gastric cancer patients. As an imaging evaluation method, spleen density is a novel tool can be used in clinical as a prognostic predictor for patients with gastric cancer.
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